MS Diagnostics Market to Reach $12.88 Billion by 2035 as 3T MRI Drives Growth
Updated
Updated · Precedence Research · May 27
MS Diagnostics Market to Reach $12.88 Billion by 2035 as 3T MRI Drives Growth
1 articles · Updated · Precedence Research · May 27
$12.88 billion is the projected size of the global multiple sclerosis diagnostics market by 2035, up from $6.20 billion in 2026 at an 8.8% CAGR.
3T MRI and other advanced neuroimaging tools are the main growth engine, as earlier and more accurate lesion detection boosts demand for lifelong diagnosis and monitoring.
MRI held the largest diagnostic share at 42% in 2025, while blood-based biomarker testing is set to expand fastest at a 15.5% CAGR as less invasive testing gains traction.
North America led with a 40% market share in 2025, but Asia-Pacific is forecast to grow fastest at 13.2% as healthcare infrastructure and disease awareness improve.
AI-based analytics and predictive diagnostic software are widening the market's scope by speeding MRI and lab analysis, identifying subtle biomarkers, and supporting earlier treatment decisions.
As AI promises near-perfect MS diagnosis, what is the real barrier to its use: cost, regulation, or clinician trust?
Can advanced diagnostics finally solve the puzzle of predicting an individual's unique multiple sclerosis disease course?
Will new blood tests create a higher standard of MS care, or widen the healthcare gap for patients globally?